Patents by Inventor Jae Hee Shin
Jae Hee Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958341Abstract: A vehicular air-conditioning apparatus includes a photocatalytic module in which light is radiated on a photocatalytic filter to sterilize the photocatalytic filter. In particular, vehicular air-conditioning apparatus incudes: a duct to allow conditioned air to flow therethrough; the photocatalytic filter mounted in the duct and coated with a photocatalytic material to remove harmful substances in reaction to light energy; and a rotation unit rotatably mounted in the duct. In particular, the rotation unit is provided with a light source to radiate light toward the photocatalytic filter. When the rotation unit is rotated, a position of the light source is changed in a rotational direction of the rotation unit such that the light is radiated on the photocatalytic filter over an increased range. Thus, a filter sterilization effect is improved over the entire area of the photocatalytic filter with reduced number of light sources.Type: GrantFiled: October 27, 2020Date of Patent: April 16, 2024Assignees: HYUNDAI MOTOR COMPANY, KIA MOTORS CORPORATIONInventors: Jae Seung Lee, Gee Young Shin, Dae Hee Lee, Dong Ho Kwon, Seung Sik Han, Myung Hoe Kim
-
Patent number: 11946934Abstract: The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.Type: GrantFiled: September 3, 2015Date of Patent: April 2, 2024Assignee: Wellmarker Bio Co., LTD.Inventors: Dong Hoon Jin, Seung Woo Hong, Jai Hee Moon, Jae Sik Shin
-
Publication number: 20240092141Abstract: An air conditioning device for a vehicle includes: a housing having an inside divided into an inflow space, a heat exchange space, and an outflow space, which are straightly arranged, and having a plurality of discharge ports, which communicates with an interior, at the inflow space; a blowing unit disposed at the inflow space of the housing and configured to blow air; a heat exchange unit disposed at the heat exchange space of the housing and configured to adjust a temperature of conditioned air by exchanging heat with air; and an opening-closing door disposed at the outflow space of the housing and configured to open and close the plurality of discharge ports such that conditioned air at an adjusted temperature selectively flows to the plurality of discharge ports. The air conditioning device adjusts the temperature of conditioned air for respective modes and reduces a flow resistance of air.Type: ApplicationFiled: March 8, 2023Publication date: March 21, 2024Applicants: HYUNDAI MOTOR COMPANY, KIA CORPORATION, DOOWON CLIMATE CONTROL CO., LTD.Inventors: Kwang Ok Han, Young Tae Song, Yong Chul Kim, Gee Young Shin, Su Yeon Kang, Jae Sik Choi, Dae Hee Lee, Byeong Moo Jang, Ung Hwi Kim, Jae Won Cha, Won Jun Joung, Byung Guk An
-
Publication number: 20240092228Abstract: A seat for a vehicle, includes a second row center seat and a second row side seat provided on a partition wall positioned rearward of a driver seat, the second row center seat may move leftward or rightward, and an interval between the seats may be increased in a state in which the second row center seat is moved in a right direction away from the second row side seat, which makes it possible to maximally prevent body contact between a passenger in the second row center seat and a passenger in the second row side seat.Type: ApplicationFiled: January 20, 2023Publication date: March 21, 2024Applicants: Hyundai Motor Company, Kia Corporation, Hyundai Transys Inc.Inventors: Jung Sang YOU, Yong Chul Kim, Dae Hee Lee, Eun Sue Kim, Jae Hoon Cho, Han Kyung Park, Jae Sung Shin, Hae Dong Kwak, Jun Sik Hwang, Gwon Hwa Bok
-
Patent number: 11932140Abstract: Disclosed is a cushion tip-up type seat for a vehicle. The cushion tip-up type seat for a vehicle is configured to perform a tip-up function of a cushion part, and to move a seat leftward and rightward to adjust an interval between left and right seats, whereby left and right spacing between occupants seated in the seats is sufficiently secured and the convenience of the occupants is improved.Type: GrantFiled: July 13, 2022Date of Patent: March 19, 2024Assignees: Hyundai Motor Company, Kia Corporation, Hyundai Transys Inc.Inventors: Dong Woo Jeong, Eun Sue Kim, Dae Hee Lee, Myung Hoe Kim, Jun Sik Hwang, Gwon Hwa Bok, Hae Dong Kwak, Jae Sung Shin, Han Kyung Park, Jae Hoon Cho
-
Publication number: 20240067056Abstract: The present disclosure relates to a vehicle rear seat including: a center seat; and side seats located on the left and right of the center seat, wherein, the center seat is capable of protruding by moving the center seat forward with respect to the side seats, and in the state in which the center seat protrudes forward, it is possible to increase an inter-passenger distance so that physical contact between the passenger of the center seat and the passenger of each of the side seats can be prevented as much as possible.Type: ApplicationFiled: March 6, 2023Publication date: February 29, 2024Inventors: Jung Sang You, Yong Chul Kim, Dae Hee Lee, Eun Sue Kim, Jae Hoon Cho, Han Kyung Park, Jae Sung Shin, Hae Dong Kwak, Jun Sik Hwang, Gwon Hwa Bok
-
Publication number: 20210317178Abstract: The present invention relates to a pharmaceutical composition including a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea, and has effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides.Type: ApplicationFiled: July 19, 2019Publication date: October 14, 2021Inventors: Kang Choon Lee, Og Yi Park, Hyoung Tae An, Eun Ji Park, Jae Hee Shin, Sung Mook Lim
-
Patent number: 11040110Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: GrantFiled: August 7, 2018Date of Patent: June 22, 2021Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 10744187Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: GrantFiled: April 27, 2018Date of Patent: August 18, 2020Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Publication number: 20180360983Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: ApplicationFiled: August 7, 2018Publication date: December 20, 2018Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae SONG, Jae Hee SHIN, Mi Ji LEE, Sung Hee HONG, Se Chang KWON, Gwan Sun LEE
-
Publication number: 20180303907Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: April 27, 2018Publication date: October 25, 2018Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae SONG, Jae Hee SHIN, Young Jin PARK, Dae Seong IM, Sung Min BAE, Se Chang KWON
-
Patent number: 10071171Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: GrantFiled: October 2, 2015Date of Patent: September 11, 2018Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 9636420Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: GrantFiled: July 23, 2009Date of Patent: May 2, 2017Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 9492507Abstract: The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: GrantFiled: April 4, 2011Date of Patent: November 15, 2016Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Publication number: 20160051696Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: ApplicationFiled: October 2, 2015Publication date: February 25, 2016Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae SONG, Jae Hee SHIN, Mi Ji LEE, Sung Hee HONG, Se Chang KWON, Gwan Sun LEE
-
Patent number: 8895281Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.Type: GrantFiled: March 18, 2010Date of Patent: November 25, 2014Assignee: Hanmi Science Co., LtdInventors: Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20130028918Abstract: The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.Type: ApplicationFiled: April 4, 2011Publication date: January 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Young Jin Park, Dae Seong Im, Sung Min Bae, Se Chang Kwon
-
Publication number: 20120003712Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.Type: ApplicationFiled: March 18, 2010Publication date: January 5, 2012Applicant: HANMI HOLDINGS CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20110200623Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: ApplicationFiled: July 23, 2009Publication date: August 18, 2011Applicant: HANMI HOLDINGS CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee